Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? by Wendy Diller Nearly three
The sad saga of Oncor Inc. is slowly coming to an end, with the purchase in November of its in situ hybridization business by Ventana Medical Systems Inc. [See Deal] . Ventana paid $5.5 millio